SCHEMBL22925487

SCHEMBL22925487

O=C(NO)c1ccc(Nc2nc(-c3ccc(C(F)(F)F)cc3)co2)nn1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.47
▸ HDAC1 Q13547 12/20 0.39
▸ HDAC6 Q9UBN7 8/20 0.39
▸ HDAC8 Q9BY41 8/20 0.39
▸ HDAC3 O15379 2/20 0.39
▸ HDAC2 Q92769 2/20 0.39
▸ ADORA3 P0DMS8 1/20 0.37
▸ HDAC4 P56524 1/20 0.37
▸ HDAC7 Q8WUI4 1/20 0.37
▸ HDAC10 Q969S8 1/20 0.37
▸ HDAC11 Q96DB2 1/20 0.37
▸ HDAC9 Q9UKV0 1/20 0.37
▸ HDAC5 Q9UQL6 1/20 0.37
▸ KDM1A O60341 1/20 0.36
▸ NLRP3 Q96P20 1/20 0.36
▸ GSTO1 P78417 1/20 0.35
▸ SMPD1 P17405 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29696288 1.00 HSD11B1 (0.47) HSD11B1HDAC1HDAC6HDAC8HDAC3
SCHEMBL22925865 0.89 HSD11B1 (0.51) HSD11B1ADORA3NLRP3GSTO1
SCHEMBL22925868 0.86 HSD11B1 (0.46) HSD11B1ADORA3NLRP3
SCHEMBL31013378 0.83 HSD11B1 (0.45) HSD11B1HDAC1HDAC6HDAC8HDAC3
SCHEMBL22925671 0.83 HSD11B1 (0.45) HSD11B1HDAC1HDAC6HDAC8HDAC3
SCHEMBL29621154 0.82 HSD11B1 (0.46) HSD11B1HDAC4HDAC7HDAC5
SCHEMBL22925866 0.82 HSD11B1 (0.46) HSD11B1HDAC4HDAC7HDAC5
SCHEMBL29696299 0.79 TRPV1 (0.45) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL22925659 0.79 TRPV1 (0.45) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL22925676 0.78 HSD11B1 (0.47) HSD11B1HDAC1HDAC6HDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 — — US disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 — — CN disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB HSD11B1 843/4885HDAC1 19/4885HDAC6 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback